NCT04803890

Brief Summary

This study is a prospective multicenter study of the duration of treatment, the success rate, the frequency of complications, and the local recurrence rate of 12 months when Radio-frequency ablation therapy is performed for the treatment of HCC using the 'No touch' technique as a combined high-frequency transmission mode with Octopus electrodes. It aims to evaluate through. In addition, the results obtained from this prospective study were as follows: 1) Patients who underwent Radio-frequency ablation therapy by puncturing an existing tumor, and 2) Patients who underwent microwave ablation during the study period. The secondary goal is to evaluate which method is more effective in reducing the treatment time and recurrence rate compared to.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2019

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

March 31, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 18, 2021

Completed
Last Updated

March 18, 2021

Status Verified

March 1, 2021

Enrollment Period

1.9 years

First QC Date

March 31, 2020

Last Update Submit

March 16, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Local tumor progression (LTP) rate

    No. of participants with LTP/ No. of participants receiving RFA

    12 months after RFA

Secondary Outcomes (2)

  • Intrahepatic distant recurrence (IDR) rate

    12 months after RFA

  • Complication rate

    12 months after RFA

Study Arms (1)

No touch radiofrequency ablation

EXPERIMENTAL

A total of 150 patients who have decided to participate in the study will be included, and prospective study will be performed to these patients for radio-frequency ablation using octopus electrodes, combined high-frequency transmission mode, and the 'No touch' technique.

Procedure: "No-Touch" Radiofrequency Ablation

Interventions

"No-Touch" Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode

No touch radiofrequency ablation

Eligibility Criteria

Age20 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Agree to the protocol's requirements and submit a consent form
  • years old-85 years old
  • Child-Pugh Class A or B7
  • Among patients with cirrhosis, patients with hepatocellular carcinoma having a size of 1 cm-3 cm suspected of MDCT or MRI performed within 60 days are considered for radio-frequency ablation
  • Patients who do not have a history of treatment for previous hepatocellular carcinoma, or who have a history of treatment for previous hepatocellular carcinoma, if recurrence has not been confirmed for at least 2 years after treatment

You may not qualify if:

  • the number of liver tumors is 3 or more
  • the maximum size of the tumor exceeds 3 cm
  • diffuse infiltrative type
  • the tumor adheres to the portal vein or hepatic vein or biliary tract of 5 mm or more
  • patients with previous medical history of hepatocellular cancer who have recurrent hepatocellular cancer within 2 years
  • the tumor is not visible even under CEUS-fusion image guidance
  • Child-Pugh class B8 or C
  • in case of invasion of liver vessels due to malignant hepatocellular carcinoma
  • severe coagulopathy
  • multiple distant metastasis
  • the situation where the probability of obtaining appropriate data suitable for the research purpose is very low

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, South Korea

Location

Study Officials

  • Jeong Min Lee, MD

    Seoul National University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 31, 2020

First Posted

March 18, 2021

Study Start

April 1, 2019

Primary Completion

March 10, 2021

Study Completion

March 10, 2021

Last Updated

March 18, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations